ID   CSPG4_RAT               Reviewed;        2326 AA.
AC   Q00657;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 2.
DT   24-JUL-2024, entry version 169.
DE   RecName: Full=Chondroitin sulfate proteoglycan 4;
DE   AltName: Full=Chondroitin sulfate proteoglycan NG2;
DE   AltName: Full=HSN tumor-specific antigen;
DE   Flags: Precursor;
GN   Name=Cspg4; Synonyms=Ng2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 30-47; 1011-1016 AND
RP   1466-1477, SUBCELLULAR LOCATION, TOPOLOGY, AND GLYCOSYLATION.
RC   TISSUE=Neuron;
RX   PubMed=1906475; DOI=10.1083/jcb.114.2.359;
RA   Nishiyama A., Dahlin K.J., Prince J.T., Johnstone S.R., Stallcup W.B.;
RT   "The primary structure of NG2, a novel membrane-spanning proteoglycan.";
RL   J. Cell Biol. 114:359-371(1991).
RN   [2]
RP   SEQUENCE REVISION TO 2047-2096.
RA   Nishiyama A., Dahlin K.J., Prince J.T., Johnstone S.R., Stallcup W.B.;
RL   J. Cell Biol. 145:1115-1115(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 556-573 AND 657-667.
RX   PubMed=8077056; DOI=10.1002/ijc.2910580514;
RA   Leger O., Johnson-Leger C., Jackson E., Coles B., Dean C.;
RT   "The chondroitin sulfate proteoglycan NG2 is a tumour-specific antigen on
RT   the chemically induced rat chondrosarcoma HSN.";
RL   Int. J. Cancer 58:700-705(1994).
RN   [4]
RP   INTERACTION WITH COL6A2, AND SUBCELLULAR LOCATION.
RX   PubMed=2269670; DOI=10.1083/jcb.111.6.3177;
RA   Stallcup W.B., Dahlin K., Healy P.;
RT   "Interaction of the NG2 chondroitin sulfate proteoglycan with type VI
RT   collagen.";
RL   J. Cell Biol. 111:3177-3188(1990).
RN   [5]
RP   INTERACTION WITH COL6A2, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=8305732; DOI=10.1091/mbc.4.11.1097;
RA   Nishiyama A., Stallcup W.B.;
RT   "Expression of NG2 proteoglycan causes retention of type VI collagen on the
RT   cell surface.";
RL   Mol. Biol. Cell 4:1097-1108(1993).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=8590808; DOI=10.1091/mbc.6.12.1819;
RA   Nishiyama A., Lin X.-H., Stallcup W.B.;
RT   "Generation of truncated forms of the NG2 proteoglycan by cell surface
RT   proteolysis.";
RL   Mol. Biol. Cell 6:1819-1832(1995).
RN   [7]
RP   INTERACTION WITH COL5A1; COL6A2; TNC AND LAMININ-1.
RX   PubMed=8824254; DOI=10.1074/jbc.271.42.26110;
RA   Burg M.A., Tillet E., Timpl R., Stallcup W.B.;
RT   "Binding of the NG2 proteoglycan to type VI collagen and other
RT   extracellular matrix molecules.";
RL   J. Biol. Chem. 271:26110-26116(1996).
RN   [8]
RP   INTERACTION WITH COL6A2, GLYCOSYLATION, DOMAIN, AND FUNCTION.
RX   PubMed=9281375; DOI=10.1006/excr.1997.3674;
RA   Burg M.A., Nishiyama A., Stallcup W.B.;
RT   "A central segment of the NG2 proteoglycan is critical for the ability of
RT   glioma cells to bind and migrate toward type VI collagen.";
RL   Exp. Cell Res. 235:254-264(1997).
RN   [9]
RP   INTERACTION WITH COL5A1 AND COL6A2, AND DOMAIN.
RX   PubMed=9099729; DOI=10.1074/jbc.272.16.10769;
RA   Tillet E., Ruggiero F., Nishiyama A., Stallcup W.B.;
RT   "The membrane-spanning proteoglycan NG2 binds to collagens V and VI through
RT   the central nonglobular domain of its core protein.";
RL   J. Biol. Chem. 272:10769-10776(1997).
RN   [10]
RP   INTERACTION WITH FGF2 AND PDGFA.
RX   PubMed=10358027; DOI=10.1074/jbc.274.24.16831;
RA   Goretzki L., Burg M.A., Grako K.A., Stallcup W.B.;
RT   "High-affinity binding of basic fibroblast growth factor and platelet-
RT   derived growth factor-AA to the core protein of the NG2 proteoglycan.";
RL   J. Biol. Chem. 274:16831-16837(1999).
RN   [11]
RP   INTERACTION WITH PLG, AND FUNCTION.
RX   PubMed=10889192; DOI=10.1074/jbc.m002290200;
RA   Goretzki L., Lombardo C.R., Stallcup W.B.;
RT   "Binding of the NG2 proteoglycan to kringle domains modulates the
RT   functional properties of angiostatin and plasmin(ogen).";
RL   J. Biol. Chem. 275:28625-28633(2000).
RN   [12]
RP   INTERACTION WITH MPDZ.
RX   PubMed=10967549;
RX   DOI=10.1002/1097-4644(20001101)79:2<213::aid-jcb50>3.0.co;2-g;
RA   Barritt D.S., Pearn M.T., Zisch A.H., Lee S.S., Javier R.T., Pasquale E.B.,
RA   Stallcup W.B.;
RT   "The multi-PDZ domain protein MUPP1 is a cytoplasmic ligand for the
RT   membrane-spanning proteoglycan NG2.";
RL   J. Cell. Biochem. 79:213-224(2000).
RN   [13]
RP   MUTAGENESIS OF SER-999 AND SER-1342, SUBCELLULAR LOCATION, GLYCOSYLATION AT
RP   SER-999, AND FUNCTION.
RX   PubMed=11493670; DOI=10.1242/jcs.114.12.2315;
RA   Stallcup W.B., Dahlin-Huppe K.;
RT   "Chondroitin sulfate and cytoplasmic domain-dependent membrane targeting of
RT   the NG2 proteoglycan promotes retraction fiber formation and cell
RT   polarization.";
RL   J. Cell Sci. 114:2315-2325(2001).
RN   [14]
RP   IDENTIFICATION OF CSPG REPEATS.
RX   PubMed=12220645; DOI=10.1016/s0014-5793(02)03195-2;
RA   Staub E., Hinzmann B., Rosenthal A.;
RT   "A novel repeat in the melanoma-associated chondroitin sulfate proteoglycan
RT   defines a new protein family.";
RL   FEBS Lett. 527:114-118(2002).
RN   [15]
RP   DOMAINS, AND FUNCTION.
RX   PubMed=12514214; DOI=10.1523/jneurosci.23-01-00175.2003;
RA   Ughrin Y.M., Chen Z.J., Levine J.M.;
RT   "Multiple regions of the NG2 proteoglycan inhibit neurite growth and induce
RT   growth cone collapse.";
RL   J. Neurosci. 23:175-186(2003).
RN   [16]
RP   PHOSPHORYLATION AT THR-2256, INTERACTION WITH PRKCA, SUBCELLULAR LOCATION,
RP   MUTAGENESIS OF THR-2256; THR-2265 AND THR-2278, AND FUNCTION.
RX   PubMed=15504744; DOI=10.1074/jbc.m411045200;
RA   Makagiansar I.T., Williams S., Dahlin-Huppe K., Fukushi J., Mustelin T.,
RA   Stallcup W.B.;
RT   "Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates
RT   polarized membrane distribution and cell motility.";
RL   J. Biol. Chem. 279:55262-55270(2004).
RN   [17]
RP   INTERACTION WITH LGALS3; ITGB1 AND ITGA3, AND FUNCTION.
RX   PubMed=15181153; DOI=10.1091/mbc.e04-03-0236;
RA   Fukushi J., Makagiansar I.T., Stallcup W.B.;
RT   "NG2 proteoglycan promotes endothelial cell motility and angiogenesis via
RT   engagement of galectin-3 and alpha3beta1 integrin.";
RL   Mol. Biol. Cell 15:3580-3590(2004).
CC   -!- FUNCTION: Proteoglycan playing a role in cell proliferation and
CC       migration which stimulates endothelial cells motility during
CC       microvascular morphogenesis. May also inhibit neurite outgrowth and
CC       growth cone collapse during axon regeneration. Cell surface receptor
CC       for collagen alpha 2(VI) which may confer cells ability to migrate on
CC       that substrate. Binds through its extracellular N-terminus growth
CC       factors, extracellular matrix proteases modulating their activity. May
CC       regulate MPP16-dependent degradation and invasion of type I collagen
CC       participating in melanoma cells invasion properties. May modulate the
CC       plasminogen system by enhancing plasminogen activation and inhibiting
CC       angiostatin. Functions also as a signal transducing protein by binding
CC       through its cytoplasmic C-terminus scaffolding and signaling proteins.
CC       May promote retraction fiber formation and cell polarization through
CC       Rho GTPase activation. May stimulate alpha-4, beta-1 integrin-mediated
CC       adhesion and spreading by recruiting and activating a signaling cascade
CC       through CDC42, ACK1 and BCAR1. May activate FAK and ERK1/ERK2 signaling
CC       cascades. {ECO:0000269|PubMed:10889192, ECO:0000269|PubMed:11493670,
CC       ECO:0000269|PubMed:12514214, ECO:0000269|PubMed:15181153,
CC       ECO:0000269|PubMed:15504744, ECO:0000269|PubMed:8305732,
CC       ECO:0000269|PubMed:9281375}.
CC   -!- SUBUNIT: Interacts with GRIP1, GRIP2 and GRIA2. Forms a ternary complex
CC       with GRIP1 and GRIA2. Interacts with ITGA4 through its chondroitin
CC       sulfate glycosaminoglycan. Interacts with BCAR1, CDC42 and ACK1.
CC       Interacts with MMP16 (By similarity). Interacts with the first PDZ
CC       domain of MPDZ. Interacts with PRKCA. Interacts with LGALS3 and the
CC       integrin composed of ITGB1 and ITGA3. Binds TNC, laminin-1, COL5A1 and
CC       COL6A2. Interacts with PLG and angiostatin. Binds FGF2 and PDGFA.
CC       {ECO:0000250, ECO:0000269|PubMed:10358027, ECO:0000269|PubMed:10889192,
CC       ECO:0000269|PubMed:10967549, ECO:0000269|PubMed:15181153,
CC       ECO:0000269|PubMed:15504744, ECO:0000269|PubMed:2269670,
CC       ECO:0000269|PubMed:8305732, ECO:0000269|PubMed:8824254,
CC       ECO:0000269|PubMed:9099729, ECO:0000269|PubMed:9281375}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15504744,
CC       ECO:0000269|PubMed:1906475}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:1906475}; Extracellular side
CC       {ECO:0000269|PubMed:1906475}. Apical cell membrane
CC       {ECO:0000269|PubMed:15504744}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:1906475}; Extracellular side
CC       {ECO:0000269|PubMed:1906475}. Cell projection, lamellipodium membrane
CC       {ECO:0000269|PubMed:15504744}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:1906475}; Extracellular side
CC       {ECO:0000269|PubMed:1906475}. Cell surface {ECO:0000269|PubMed:2269670,
CC       ECO:0000269|PubMed:8305732, ECO:0000269|PubMed:8590808}. Note=Localizes
CC       to the plasma membrane of oligodendrocytes (By similarity). Localized
CC       at the apical plasma membrane it relocalizes to the lamellipodia of
CC       astrocytoma upon phosphorylation by PRKCA (PubMed:15504744). Localizes
CC       to the retraction fibers (PubMed:11493670). A fraction may undergo cell
CC       surface proteolysis and secretion. {ECO:0000250|UniProtKB:Q8VHY0,
CC       ECO:0000269|PubMed:11493670, ECO:0000269|PubMed:15504744}.
CC   -!- TISSUE SPECIFICITY: Neural cells and also extraneural tissues,
CC       especially in the developing mesenchyme.
CC   -!- DEVELOPMENTAL STAGE: The level of expression is highest on immature,
CC       proliferating cells and decreases as these cells differentiate.
CC   -!- PTM: N-glycosylated.
CC   -!- PTM: O-glycosylated; contains glycosaminoglycan chondroitin sulfate
CC       which are required for proper localization and function in stress fiber
CC       formation. Involved in interaction with MMP16 and ITGA4.
CC   -!- PTM: Phosphorylation by PRKCA regulates its subcellular location and
CC       function in cell motility. {ECO:0000269|PubMed:15504744}.
CC   -!- MISCELLANEOUS: Valuable marker for several incompletely differentiated
CC       precursor cells.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X56541; CAA39884.2; -; mRNA.
DR   PIR; S16025; A61208.
DR   RefSeq; NP_112284.1; NM_031022.1.
DR   AlphaFoldDB; Q00657; -.
DR   SMR; Q00657; -.
DR   BioGRID; 249551; 1.
DR   STRING; 10116.ENSRNOP00000023326; -.
DR   GlyCosmos; Q00657; 16 sites, No reported glycans.
DR   GlyGen; Q00657; 16 sites.
DR   iPTMnet; Q00657; -.
DR   PhosphoSitePlus; Q00657; -.
DR   SwissPalm; Q00657; -.
DR   PaxDb; 10116-ENSRNOP00000023326; -.
DR   ABCD; Q00657; 8 sequenced antibodies.
DR   GeneID; 81651; -.
DR   KEGG; rno:81651; -.
DR   UCSC; RGD:619942; rat.
DR   AGR; RGD:619942; -.
DR   CTD; 1464; -.
DR   RGD; 619942; Cspg4.
DR   eggNOG; KOG3597; Eukaryota.
DR   InParanoid; Q00657; -.
DR   OrthoDB; 4072625at2759; -.
DR   PhylomeDB; Q00657; -.
DR   Reactome; R-RNO-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   Reactome; R-RNO-2022870; Chondroitin sulfate biosynthesis.
DR   Reactome; R-RNO-2022923; Dermatan sulfate biosynthesis.
DR   Reactome; R-RNO-2024101; CS/DS degradation.
DR   PRO; PR:Q00657; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042995; C:cell projection; ISO:RGD.
DR   GO; GO:0009986; C:cell surface; IEA:UniProtKB-SubCell.
DR   GO; GO:0031258; C:lamellipodium membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0001726; C:ruffle; ISO:RGD.
DR   GO; GO:0005518; F:collagen binding; IPI:UniProtKB.
DR   GO; GO:0015026; F:coreceptor activity; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; ISO:RGD.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0008347; P:glial cell migration; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; ISO:RGD.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IMP:RGD.
DR   GO; GO:0016322; P:neuron remodeling; IDA:RGD.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; ISO:RGD.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISO:RGD.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISO:RGD.
DR   GO; GO:0097178; P:ruffle assembly; ISO:RGD.
DR   GO; GO:0006929; P:substrate-dependent cell migration; ISO:RGD.
DR   GO; GO:0048771; P:tissue remodeling; IEA:UniProtKB-KW.
DR   CDD; cd00110; LamG; 2.
DR   Gene3D; 2.60.120.200; -; 2.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR039005; CSPG_rpt.
DR   InterPro; IPR051561; FRAS1_ECM.
DR   InterPro; IPR001791; Laminin_G.
DR   PANTHER; PTHR45739:SF12; CHONDROITIN SULFATE PROTEOGLYCAN 4-LIKE ISOFORM X2; 1.
DR   PANTHER; PTHR45739; MATRIX PROTEIN, PUTATIVE-RELATED; 1.
DR   Pfam; PF16184; Cadherin_3; 12.
DR   Pfam; PF00054; Laminin_G_1; 1.
DR   Pfam; PF02210; Laminin_G_2; 1.
DR   SMART; SM00282; LamG; 2.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 2.
DR   PROSITE; PS51854; CSPG; 15.
DR   PROSITE; PS50025; LAM_G_DOMAIN; 2.
PE   1: Evidence at protein level;
KW   Angiogenesis; Cell membrane; Cell projection; Developmental protein;
KW   Differentiation; Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Membrane; Phosphoprotein; Proteoglycan; Reference proteome; Repeat; Signal;
KW   Tissue remodeling; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..29
FT                   /evidence="ECO:0000269|PubMed:1906475"
FT   CHAIN           30..2326
FT                   /note="Chondroitin sulfate proteoglycan 4"
FT                   /id="PRO_0000026695"
FT   TOPO_DOM        30..2225
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:1906475"
FT   TRANSMEM        2226..2250
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        2251..2326
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:1906475"
FT   DOMAIN          30..193
FT                   /note="Laminin G-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   DOMAIN          203..381
FT                   /note="Laminin G-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   REPEAT          429..524
FT                   /note="CSPG 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          554..646
FT                   /note="CSPG 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          663..765
FT                   /note="CSPG 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          784..882
FT                   /note="CSPG 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          902..993
FT                   /note="CSPG 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1022..1114
FT                   /note="CSPG 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1130..1220
FT                   /note="CSPG 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1242..1341
FT                   /note="CSPG 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1360..1453
FT                   /note="CSPG 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1477..1567
FT                   /note="CSPG 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1585..1683
FT                   /note="CSPG 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1708..1807
FT                   /note="CSPG 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1836..1928
FT                   /note="CSPG 13"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1945..2033
FT                   /note="CSPG 14"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          2042..2151
FT                   /note="CSPG 15"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REGION          30..640
FT                   /note="Globular or compact configuration stabilized by
FT                   disulfide bonds"
FT   REGION          30..640
FT                   /note="Neurite growth inhibition"
FT   REGION          575..1044
FT                   /note="Interaction with COL6A2"
FT   REGION          632..1450
FT                   /note="Interaction with COL5A1"
FT   REGION          1590..2225
FT                   /note="Neurite growth inhibition"
FT   REGION          1591..2225
FT                   /note="Cysteine-containing"
FT   REGION          2187..2210
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           2324..2326
FT                   /note="PDZ-binding"
FT   COMPBIAS        2192..2210
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2256
FT                   /note="Phosphothreonine; by PKC/PRKCA"
FT                   /evidence="ECO:0000269|PubMed:15504744"
FT   CARBOHYD        130
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        349
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        428
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        686
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        773
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        999
FT                   /note="O-linked (Xyl...) (chondroitin sulfate) serine"
FT                   /evidence="ECO:0000269|PubMed:11493670"
FT   CARBOHYD        1135
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1206
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1368
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1453
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1649
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1913
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2020
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2038
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2044
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2079
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        170..193
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   DISULFID        355..381
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   MUTAGEN         999
FT                   /note="S->A: No chondroitin sulfate attachment. Loss of
FT                   localization to the retraction fibers."
FT                   /evidence="ECO:0000269|PubMed:11493670"
FT   MUTAGEN         1342
FT                   /note="S->A: No effect on chondroitin sulfate attachment."
FT                   /evidence="ECO:0000269|PubMed:11493670"
FT   MUTAGEN         2256
FT                   /note="T->E: Localized to the lamellipodia. Increases cell
FT                   motility independently of PRKCA activation."
FT                   /evidence="ECO:0000269|PubMed:15504744"
FT   MUTAGEN         2256
FT                   /note="T->V: Apically localized. Loss of PRKCA-dependent
FT                   cell motility."
FT                   /evidence="ECO:0000269|PubMed:15504744"
FT   MUTAGEN         2265
FT                   /note="T->E: Behaves as wild-type."
FT                   /evidence="ECO:0000269|PubMed:15504744"
FT   MUTAGEN         2265
FT                   /note="T->V: Behaves as wild-type."
FT                   /evidence="ECO:0000269|PubMed:15504744"
FT   MUTAGEN         2278
FT                   /note="T->E: Behaves as wild-type."
FT                   /evidence="ECO:0000269|PubMed:15504744"
FT   MUTAGEN         2278
FT                   /note="T->V: Behaves as wild-type."
FT                   /evidence="ECO:0000269|PubMed:15504744"
FT   CONFLICT        1391..1392
FT                   /note="LG -> FP (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   2326 AA;  251909 MW;  FA3E3BCEDB7E5EF5 CRC64;
     MLLSPGHPLS APALALILTL ALLVRSTAPA SFFGENHLEV PVPSALTRVD LLLQFSTSQP
     EALLLLAAGQ TDHLLLQLQS GHLQVRLALG QNELSLQTPA DTVLSDSTTH TVVLTVSNSW
     AVLSVDGVLN TSAPIPKASH LKVPYGLFVG SSGSLDLPYL KGISRPLRGC LHSAILNGRN
     LLRPLTPDVH EGCAEEFSAG DEVGLGFSGP HSLAAFPAWS TREEGTLEFT LTTRSQQAPL
     AFQAGDKRGN FIYVDIFEGH LRAVVEKGQG TMLLRNSVPV ADGQPHEVSV HIDVHRLEIS
     VDQYPTRTFN RGVLSYLEPR GSLLLGGLDT EASRHLQEHR LGLTPGAANI SLVGCIEDFS
     VNGRRLGLRD AWLTRDMAAG CRPEEDEYEE EVYGPFEAFS TLAPEAWPVM DLPEPCVPEP
     GLPAVFANFT QLLTISPLVV AEGGTAWLEW RHVQPTLDLT EAELRKSQVL FSVSQGARHG
     ELELDIPGAQ TRKMFTLLDV VNRKARFVHD GSEDTSDQLM LEVSVTSRAP VPSCLRRGQI
     YILPIQVNPV NDPPRIVFPH GSLMVILEHT QKPLGPEIFQ AYDPDSACEG LTIQLLGVSA
     SVPVEHRDQP GEPVTEFSCR DLEAGNIVYV HRGGPAQDLT FRVSDGMQAS GPATLKVVAV
     RPAIQILHNT GLRLAQGSAA AILPANLSVE TNAVGQDVSV LFRVTGTLQF GELQKQGAGG
     VEGTEWWDTL AFHQRDVEQG RVRYLSTDPQ HHTQDTVEDL TLEVQVGQET LSNLSFPVTI
     QRATVWMLQL EPLHTQNPHQ ETLTSAHLEA SLEEEGEGGP YPHIFHYELV QAPRRGNLLL
     QGTRLSDGQS FSQSDLQAGR VTYRATTRTS EAAEDSFRFR VTSPPHFSPL YTFPIHIGGD
     PNAPVLTNVL LMVPEGGEGV LSADHLFVKS LNSASYLYEV MEQPHHGSLA WRDPKGRATP
     VTSFTNEDLL HGRLVYQHDD SETIEDDIPF VATRQGEGSG DMAWEEVRGV FRVAIQPVND
     HAPVQTISRV FHVARGGQRL LTTDDVAFSD ADSGFSDAQL VLTRKDLLFG SIVAMEEPTR
     PIYRFTQEDL RKKQVLFVHS GADHGWLQLQ VSDGQHQATA MLEVQASEPY LHVANSSSLV
     VPQGGQGTID TAVLHLDTNL DIRSGNEVHY HVTAGPHWGQ LLRDGQSVTS FSQRDLLDGA
     ILYSHNGSLS PQDTLALSVA AGPVHTSTVL QVTIALEGPL APLQLVQHKR IYVFQGEAAE
     IRRDQLEVVQ EAVLPADIMF SLRSPPNAGY LVMVSHGASA DGPPSLDPVQ RFSQEAINSG
     RVLYLHSRPG AWSDSFSLDV ASGLGDPLEG ISVELEVLPT VIPLDVQNFS VPEGGTRTLA
     PPLIQITGPY LGTLPGLVLQ VLEPPQHGAL QKEDRPQDGT LSTFSWREVE EQLIRYVHDG
     SETQTDGFIL LANASEMDRQ SQPMAFTITI LPVNDQPPVI TTNTGLQIWE GAIVPIPPEA
     LRGIDSDSGP EDLVYTIEQP SNGRIALRVA PDAEAHRFTQ AQLDSGLVLF SHRGALEGGF
     HFDLSDGVHT SPGHFFRVVA QKQVLLSLEG SRKLTVCPES VQPLSSQSLS ASSSTGSDPR
     HLLYQVVRGP QLGRLLHAQQ GSAEEALVNF TQAEVNAGNI LYEHEISSEP FWEAHDTIGL
     LLSSSPARDL AATLAVTVSF DAACPQRPSR LWRNKGLWVP EGQRAKITVA ALDAANLLAS
     VPASQRGRHD VLFQITQFPT RGQLLVSEEP LHARRPHFLQ SELTAGQLVY AHGGGGTQQD
     GFRFRAHLQG PTGASVAGPQ TSEAFVITVR DVNERPPQPQ ASIPLRITRG SRAPVSRAQL
     SVVDPDSAPG EIEYEVQRAP HNGFLSLAGD NTGPVTHFTQ ADVDAGRLAF VANGSSVAGV
     FQLSMSDGAS PPIPMSLAVD VLPSTIEVQL RAPLEVPQAL GRSSLSRQQL QVISDREEPD
     VAYRLTQGPL YGQVLVGGQP ASAFSQLQVD QGDVVFAFTN FSSSQDHFKV LALARGVNAS
     ATVNVTVQAL LHVWAGGPWP QGTTLRLDPT VLDASELANR TGSMPRFRLL EGPRYGRVVR
     VSQGRAESRT NQLVEDFTQQ DLEEGRLGLE VGRPEGRSTG PTGDRLTLEL QATGVPPAVA
     LLDFATEPYH AAKFYKVTLL SVPEAARTET EKTGKSTPTG QPGQAASSPM PTVAKSGFLG
     FLEANMFSVI IPVCLVLLLL ALILPLLFYL RKRNKTGKHD VQVLTAKPRN GLAGDTETFR
     KVEPGQAIPL TTVPGQGPPP GGQPDPELLQ FCRTPNPALR NGQYWV
//
